Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2021
Novel adjuvant options for cutaneous melanomaF Dimitriou, G V Long, A M Menzies
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2021
Immunotherapy use outside clinical trial populations: never say never?K Rzeniewicz, J Larkin, A M Menzies, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2021
FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanomaF Dimitriou, S N Lo, A C Tan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 21, 2020
Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategyJ Haanen, M S Ernstoff, Y Wang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 24, 2018
FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanomaA C Tan, L Emmett, S Lo, et al.
Cancer Immunology, Immunotherapy : CII|June 25, 2025
Dissecting response to neoadjuvant immunotherapy-treated melanoma using cancer-immunity cycle-associated signaturesS C M A Wijnen, P Dimitriadis, I L M Reijers, et al.
Skin Health and Disease|June 6, 2022
Cutaneous sarcoidosis due to immune-checkpoint inhibition and exacerbated by a novel BRAF dimerization inhibitorJ P Pham, P Star, S Wong, et al.
European Journal of Cancer Care|October 13, 2016
Advanced cancer patients' attitudes towards, and experiences with, screening for somatic mutations in tumours: a qualitative studyR Liang, B Meiser, S Smith, et al.
Immuno-Oncology Technology|November 24, 2025
Sites of metastases before systemic treatment influence progression patterns and survival in stage IV melanoma patientsI A Vergara, S N Lo, I Li, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanomaM H Pollack, A Betof, H Dearden, et al.
Pageof 4